Skip to main content Accessibility help
×
Home
Hostname: page-component-559fc8cf4f-s65px Total loading time: 0.431 Render date: 2021-03-04T17:29:42.479Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract

Published online by Cambridge University Press:  16 September 2011

Takashi Hashimoto
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Yoshiaki Ozaki
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Masashi Mizuno
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Masaru Yoshida
Affiliation:
Department of Internal Medicine, Kobe University, Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe, 650-0017Hyogo, Japan
Yosuke Nishitani
Affiliation:
Organization of Advanced Science and Technology, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Takeshi Azuma
Affiliation:
Department of Internal Medicine, Kobe University, Graduate School of Medicine, 7-5-1 Kusunoki, Chuo, Kobe, 650-0017Hyogo, Japan
Akitoshi Komoto
Affiliation:
Ogurayayamamoto Company, 2-124 Wakabayashi, Yao, Osaka581-0038, Japan
Takashi Maoka
Affiliation:
Research Institute for Production Development, 15 Shimogamo-morimoto, Sakyo, Kyoto606-0805, Japan
Yuka Tanino
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Kazuki Kanazawa
Affiliation:
Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501Hyogo, Japan
Corresponding
E-mail address:
Rights & Permissions[Opens in a new window]

Abstract

Dietary fucoxanthin has been reported to exert several physiological functions, and fucoxanthinol is considered to be the primary active metabolite of fucoxanthin. However, there is no information about the pharmacokinetics of fucoxanthinol in human subjects. In the present study, eighteen human volunteers were orally administered kombu extract containing 31 mg fucoxanthin, and their peripheral blood was collected 5 min before and 0·5, 1, 2, 4, 8 and 24 h after the treatment. Plasma fucoxanthinol concentrations were measured by HPLC, and the pharmacokinetics of fucoxanthinol were as follows: maximum concentration, 44·2 nmol/l; time at maximum concentration, 4 h; terminal half-time, 7·0 h; area under the curve (AUC) for 1–24 h, 578·7 nmol/l × h; AUC(∞), 663·7 nmol/l × h. In addition to fucoxanthinol, we also attempted to detect amarouciaxanthin A, a hepatic metabolite of fucoxanthinol, using HPLC, but it was not present in the volunteers' plasma. On the other hand, a peak that was suspected to represent the cis-isomer of fucoxanthinol was found in the HPLC chromatogram. By comparing the present results with those of a previous study using mice, we found that the bioavailability and metabolism of fucoxanthinol differ between human subjects and mice.

Type
Short Communication
Copyright
Copyright © The Authors 2011

Fucoxanthin is one of the xanthophylls found in brown seaweed such as kombu (Laminaria japonica), hijiki (Sargassum fusiforme) and wakame (Undaria pinnatifida)(Reference Haugan, Aakermann and Liaaen-Jensen1). It has been reported to have several physiological functions including anti-carcinogenic(Reference Okuizumi, Takahashi and Yamane2Reference Azuma, Hashimoto and Nomura7) and anti-obese activities(Reference Maeda, Hosokawa and Sashima8, Reference Maeda, Hosokawa and Sashima9) in several studies involving experimental animals and human subjects and murine cell lines. Recently, brown seaweed extract has been used as a source of fucoxanthin for commercial nutritional supplements worldwide. Most dietary fucoxanthin is absorbed as fucoxanthinol, a hydrolysed metabolite, in the small intestine(Reference Sugawara, Baskaran and Tsuzuki10). Previous studies have suggested that fucoxanthinol is further converted to amarouciaxanthin A in the liver(Reference Asai, Sugawara and Ono11). Thus, these metabolites are considered to be the active forms that exert physiological functions in the body. The bioavailability of these metabolites is required for the proper and safe usage of dietary fucoxanthin. Recent studies have described the pharmacokinetics of fucoxanthinol and amarouciaxanthin A, and demonstrated their accumulation after the oral administration of fucoxanthin to mice(Reference Hashimoto, Ozaki and Taminato12, Reference Ozaki, Katsumata and Uehara13). However, there are no reports about the pharmacokinetics of fucoxanthin and its metabolites in human subjects, although Asai et al. (Reference Asai, Yonekura and Nagao14) reported that fucoxanthinol was detectable at a concentration of 0·8 nmol/l in human plasma after the daily intake of wakame containing 6·1 mg fucoxanthin for 1 week.

In the present study, kombu extract containing 31 mg fucoxanthin was orally administered to human volunteers, and the pharmacokinetics of fucoxanthin and its metabolites were investigated.

Experimental methods

Reagents

Fucoxanthin, fucoxanthinol and amarouciaxanthin A were prepared as described previously(Reference Hashimoto, Ozaki and Taminato12). Astaxanthin was purchased from Extrasyntèse (Genay, France). Kombu extract was provided by Oryza Oil & Fat Chemical (Aichi, Japan). All other reagents were of the highest grade commercially available.

Human study

The study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by the Ethics Committee at Kobe University Graduate School of Medicine (permission no. 615). Written informed consent was obtained from all subjects. Verbal consent was witnessed and formally recorded. A total of eighteen volunteers (ten males and eight females), with a mean age of 33 (range 22–63) years, a mean body weight (BW) of 60 (range 45–71) kg and a mean BMI of 21·8 (range 19·0–24·6) kg/m2, were enrolled in the single oral dose study. The participants were told to refrain from consuming brown algae such as kombu and wakame for 1 week and then fasted for 12 h. They were orally administered 10 ml of kombu extract dissolved in medium-chain TAG, which contained 31 mg fucoxanthin. Their peripheral blood was collected 5 min before the treatment and 0·5, 1, 2, 4, 8 and 24 h after the treatment. Plasma samples were prepared by centrifugation at 1000 g for 10 min at 4°C and stored at − 80°C until the analysis.

HPLC analysis of fucoxanthin and its metabolites

Plasma (2·0 ml) was mixed with 20 μl of 20 μm-astaxanthin, as an internal standard, and added to 2·5 ml dichloromethane–methanol (1:2, v/v). This was then extracted three times with 5·0 ml dichloromethane. The dichloromethane layer was collected after centrifugation at 1500 g for 15 min, evaporated and then dissolved in dimethyl sulfoxide–methanol (1:1, v/v). Then, 50 μl of the samples were subjected to HPLC analysis to determine the levels of metabolites, as described previously(Reference Hashimoto, Ozaki and Taminato12).

Pharmacokinetic analysis

The pharmacokinetic parameters of fucoxanthinol were calculated from the changes in its concentration over time using a non-compartmental pharmacokinetic analysis program(Reference Tabata, Yamaoka and Kaibara15).

Results and discussion

To investigate the pharmacokinetics of dietary fucoxanthin and its metabolites in human plasma, eighteen healthy volunteers were orally administered 10 ml of kombu extract containing 31 mg fucoxanthin, and their peripheral blood was collected 5 min before and 0·5, 1, 2, 4, 8 and 24 h after the treatment. Fucoxanthinol was detectable in the plasma of all participants, but fucoxanthin was not (Fig. 1(A)). The plasma concentration of fucoxanthinol increased until 4 h after the treatment and then gradually decreased to 7·6 (sd 0·8) nmol/l at 24 h after the treatment (Fig. 1(B)). The pharmacokinetic parameters described below were calculated from these data. The maximum concentration (C max), time at maximum concentration (T max), terminal half-life (t 1/2), area under the curve (AUC) for 1–24 h and AUC(∞) of fucoxanthinol in plasma were 44·2 nmol/l, 4 h, 7·0 h, 578·7 nmol/l × h and 663·7 nmol/l × h, respectively. Novotny et al. (Reference Novotny, Kurilich and Britz16) reported that the AUC of [13C]β-carotene and [13C]lutein in human subjects fed isotopically labelled kale were 13·6 and 42·8 μm, respectively, when the ingested doses of the labelled carotenoids were 34 and 33 μm, respectively. Mercke Odeberg et al. (Reference Mercke Odeberg, Lignell and Pettersson17) demonstrated that the AUC(∞) of astaxanthin was 2·26 μmol/l × h after the administration of a single oral dose of 40 mg (67 μmol) astaxanthin to healthy male volunteers, and changes in the formulation enhanced the AUC (range 3·71–8·31 μmol/l × h). Thus, the bioavailability of fucoxanthinol seems to be lower than that of other dietary carotenoids such as β-carotene, lutein and astaxanthin.

Fig. 1 (A) Representative HPLC chromatograms of human plasma. HPLC analysis was performed as described in the Experimental methods section. Chromatograms of the plasma extract obtained at (a) 5 min before and (b) 4 h after the administration of a single dose of 31 mg fucoxanthin-containing kombu extract. (c) Chromatogram of fucoxanthin (retention time, 11·9 min), fucoxanthinol (13·8 min) and amarouciaxanthin A (16·4 min) standards and astaxanthin (20·4 min) as an internal standard. (B) Time-course profile of fucoxanthinol in human plasma after the administration of a single dose of fucoxanthin. Eighteen volunteers were administered kombu extract containing 31 mg fucoxanthin. The amount of fucoxanthinol in their plasma was determined by HPLC as described in the Experimental methods section. Values are means, with standard deviations represented by vertical bars, n 18.

Recently, we have reported the pharmacokinetics of fucoxanthinol in mouse plasma after the administration of a single oral dose of 160 nmol (0·105 mg) fucoxanthin, i.e. 3·5 mg fucoxanthin/kg BW(Reference Hashimoto, Ozaki and Taminato12). The T max of fucoxanthinol was 4 h, and the plasma concentration of fucoxanthinol decreased gradually until 24 h. The time-course profile of fucoxanthinol in human plasma obtained in the present study was similar to that detected in mice. On the other hand, our previous study(Reference Hashimoto, Ozaki and Taminato12) also indicated that the C max, t 1/2 and AUC(∞) of fucoxanthinol were 132 nmol/l, 4·5 h and 1430 nmol/l × h, respectively, and that the plasma concentration of fucoxanthinol at 24 h after its administration was 8·2 (sd 4·5) nmol/l. The mean dose in the present study was 0·52 mg fucoxanthin/kg BW (range 0·44–0·69 mg/kg BW), which was one-seventh (15 %) of that administered to the mice in our previous study(Reference Hashimoto, Ozaki and Taminato12). However, the C max and AUC(∞) of fucoxanthinol in the human study were estimated to be 33 and 46 % of the values found in mice, respectively. Furthermore, the t 1/2 of fucoxanthinol in human subjects was 7·0 h, and its concentration at 24 h after its administration was 7·6 (sd 3·2) nmol/l (Fig. 1(B)). These results suggest that the bioavailability of fucoxanthinol is higher in human subjects than in mice. Mordenti(Reference Mordenti18) reported that smaller, short-lived animals generally clear drugs from their bodies more rapidly than larger, long-lived animals, and that the pharmacokinetic profiles of different species were strikingly different, with elimination being most rapid for mice and least rapid for human subjects among the species compared. This seems to be the reason why the bioavailability of fucoxanthinol in human subjects is higher than that in mice.

In the present study, amarouciaxanthin A was not detected in the blood of any of the participants (Fig. 1(A)). This result agrees with the findings of a previous human study(Reference Asai, Yonekura and Nagao14). On the other hand, amarouciaxanthin A was detected as a hepatic metabolite of fucoxanthinol in mice in vivo (Reference Asai, Sugawara and Ono11). Also, our previous mouse study(Reference Hashimoto, Ozaki and Taminato12) established the pharmacokinetics of amarouciaxanthin A, i.e. C max, 230 nmol/l; t 1/2, 6·7 h; AUC(∞), 2040 nmol/l × h. Kistler et al. (Reference Kistler, Liechti and Pichard19) reported that the metabolism of astaxanthin, a xanthophyll, differed between human subjects and rats because culturing human hepatocytes with astaxanthin and the single oral administration of astaxanthin to rats resulted in the induction of different P450 and the production of different metabolites. Thus, fucoxanthinol might also induce different P450 and be converted to unknown metabolites. On the other hand, Asai et al. (Reference Asai, Yonekura and Nagao14) also detected the cis-isomer of fucoxanthinol in human plasma after the daily intake of wakame containing 6·1 mg fucoxanthin for 1 week. In the present study, an unknown metabolite (peak I in Fig. 1(A)) was detected at 15·1 min. This peak might have been due to the cis-isomer of fucoxanthinol. These results indicate that xanthophylls are metabolised differently in human subjects and rodents. Further studies are needed to examine this assumption in relation to the metabolism of fucoxanthin and fucoxanthinol.

An additional experiment, in which healthy volunteers (five males and five females) with a mean age of 26 (range 22–34) years and a mean BMI of 21·5 (range 19·1–23·9) kg/m2 were administered five soft-gel capsules containing a total of 0·31 mg fucoxanthin daily for 28 d, showed that this dose did not cause the accumulation of fucoxanthin metabolites in the body (data not shown). This amount is almost equal to the amount of brown algae that is consumed each day in the Japanese diet according to a previous report(Reference Toyokawa20). Moreover, no harmful effects were observed in general blood tests or biochemical blood tests (data not shown), suggesting that the daily intake of fucoxanthin from sea algae is safe. Although the outer colour and internal tissues of mice became orange when they were fed a 0·1 % fucoxanthin-containing diet for 1 month (approximately 100 mg/kg BW per d), they did not suffer any toxic symptoms(Reference Ozaki, Katsumata and Uehara13). It seems that the toxicity of dietary fucoxanthin is low, even if its metabolites accumulate at low levels. These results suggest that the dose (31 mg; mean intake 0·52 mg/kg BW) used in the present study is safe and is sufficient to induce health benefits.

The present study is the first report on the pharmacokinetics of fucoxanthinol, which is the primary metabolite of fucoxanthin and is considered to be the active form in the body, and also discussed the accumulation of fucoxanthin metabolites in human subjects. Recently, Abidov et al. (Reference Abidov, Ramazanov and Seifulla21) demonstrated that the administration of 2·4 mg fucoxanthin for 16 weeks to obese premenopausal women with non-alcoholic fatty liver disease improved their liver function test results; however, they did not provide any data about the accumulation of fucoxanthin metabolites. Further studies on metabolite accumulation after the administration of fucoxanthin at functional concentrations are needed to clarify the safety of administering fucoxanthin to humans.

Acknowledgements

This study was supported by the Research and Development Program for New Bio-industry Initiatives (2006–10) of the Bio-oriented Technology Research Advancement Institution, Japan. T. H., M. M. and K. K. contributed to the design of the study and prepared the manuscript. T. H., Y. O., M. Y., Y. N. and T. A. performed the human studies and analyses. Y. O., Y. T., A. K. and T. M. purified fucoxanthin, fucoxanthinol and amarouciaxanthin A. All authors contributed to and approved the final draft of the manuscript. The authors declare that there are no conflicts of interest.

References

1Haugan, JA, Aakermann, T & Liaaen-Jensen, S (1992) Isolation of fucoxanthin and peridinin. Methods Enzymol 213, 231245.CrossRefGoogle Scholar
2Okuizumi, J, Takahashi, T, Yamane, T, et al. (1993) Inhibitory effects of fucoxanthin, a natural carotenoid, on N-ethyl-N(-nitro-N-nitrosoguanidine-induced mouse duodenal carcinogenesis. Cancer Lett 68, 159168.CrossRefGoogle Scholar
3Das, SK, Hashimoto, T, Baba, M, et al. (2006) Japanese kelp (kombu) extract suppressed the formation of aberrant crypt foci in azoxymethane challenged mouse colon. J Clin Biochem Nutr 38, 119125.CrossRefGoogle Scholar
4Kotake-Nara, E, Kushiro, M, Zhang, H, et al. (2001) Carotenoids affect proliferation of human prostate cancer cells. J Nutr 131, 33033306.CrossRefGoogle ScholarPubMed
5Hosokawa, M, Kudo, M, Maeda, H, et al. (2004) Fucoxanthin induces apoptosis and enhances the antiproliferative effect of the PPARγ ligand, troglitazone, on colon cancer cells. Biochim Biophys Acta 1675, 113119.CrossRefGoogle ScholarPubMed
6Das, SK, Hashimoto, T, Shimizu, K, et al. (2005) Fucoxanthin induces cell cycle arrest at G0/G1 phase in human colon carcinoma cells through up-regulation of p21WAF1/Cip1. Biochim Biophys Acta 1726, 328335.CrossRefGoogle ScholarPubMed
7Azuma, Y, Hashimoto, T, Nomura, H, et al. (2008) Fucoxanthin induced apoptosis in human hepatocarcinoma HepG2 cells. J Clin Biochem Nutr 43, 273276.Google Scholar
8Maeda, H, Hosokawa, M, Sashima, T, et al. (2006) Fucoxanthin and its metabolite, fucoxanthinol, suppress adipocyte differentiation in 3T3-L1 cells. Int J Mol Med 18, 147152.Google ScholarPubMed
9Maeda, H, Hosokawa, M, Sashima, T, et al. (2005) Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun 332, 392397.CrossRefGoogle ScholarPubMed
10Sugawara, T, Baskaran, V, Tsuzuki, W, et al. (2002) Brown algae fucoxanthin is hydrolyzed to fucoxanthinol during absorption by Caco-2 human intestinal cells and mice. J Nutr 132, 946951.CrossRefGoogle ScholarPubMed
11Asai, A, Sugawara, T, Ono, H, et al. (2004) Biotransformation of fucoxanthinol into amaroucixanthin A in mice and HepG2 cells: formation and cytotoxicity of fucoxanthin metabolites. Drug Metab Dispos 32, 205211.CrossRefGoogle ScholarPubMed
12Hashimoto, T, Ozaki, Y, Taminato, M, et al. (2009) The distribution and accumulation of fucoxanthin and its metabolites after oral-administration in mice. Br J Nutr 102, 242248.CrossRefGoogle ScholarPubMed
13Ozaki, Y, Katsumata, S, Uehara, M, et al. (2008) Accumulation of fucoxanthin and its metabolites in mice after ad libitum administration of kombu extract-containing diet for one month. J Clin Biochem Nutr 43, (Suppl. 1), 269272.Google Scholar
14Asai, A, Yonekura, L & Nagao, A (2008) Low bioavailability of dietary epoxyxanthophylls in humans. Br J Nutr 100, 273277.CrossRefGoogle ScholarPubMed
15Tabata, K, Yamaoka, K, Kaibara, A, et al. (1999) Moment analysis program available on Microsoft Excel. Xenobio Metabol Dispos 14, 286293.Google Scholar
16Novotny, JA, Kurilich, AC, Britz, SJ, et al. (2005) Plasma appearance of labeled β-carotene, lutein, and retinol in humans after consumption of isotopically labeled kale. J Lipid Res 46, 18961903.CrossRefGoogle ScholarPubMed
17Mercke Odeberg, J, Lignell, Å, Pettersson, A, et al. (2003) Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci 19, 299304.CrossRefGoogle ScholarPubMed
18Mordenti, J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharma Sci 75, 10281040.CrossRefGoogle ScholarPubMed
19Kistler, A, Liechti, H, Pichard, L, et al. (2002) Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch Toxicol 75, 665675.CrossRefGoogle ScholarPubMed
20Toyokawa, H (1978) Nutritional status in Japan from the viewpoint of numerical ecology. Soc Sci Med 12, 517524.Google ScholarPubMed
21Abidov, M, Ramazanov, Z, Seifulla, R, et al. (2010) The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab 12, 7281.CrossRefGoogle ScholarPubMed

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 175
Total number of PDF views: 531 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 4th March 2021. This data will be updated every 24 hours.

Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Pharmacokinetics of fucoxanthinol in human plasma after the oral administration of kombu extract
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *